It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGEN’s FA Score shows that 0 FA rating(s) are green whileEBS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGEN’s TA Score shows that 5 TA indicator(s) are bullish while EBS’s TA Score has 4 bullish TA indicator(s).
AGEN (@Biotechnology) experienced а +27.98% price change this week, while EBS (@Pharmaceuticals: Other) price change was +0.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +62.47%. For the same industry, the average monthly price growth was +4.88%, and the average quarterly price growth was +67.74%.
AGEN is expected to report earnings on May 12, 2025.
EBS is expected to report earnings on Nov 05, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Other (+62.47% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
AGEN | EBS | AGEN / EBS | |
Capitalization | 171M | 120M | 143% |
EBITDA | -81.06M | -518.2M | 16% |
Gain YTD | 127.007 | -27.510 | -462% |
P/E Ratio | 0.23 | 17.73 | 1% |
Revenue | 99.5M | 1.02B | 10% |
Total Cash | 18.5M | 112M | 17% |
Total Debt | 92M | 860M | 11% |
AGEN | EBS | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 34 | 45 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AGEN's Valuation (50) in the Biotechnology industry is in the same range as EBS (50). This means that AGEN’s stock grew similarly to EBS’s over the last 12 months.
AGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EBS (100). This means that AGEN’s stock grew similarly to EBS’s over the last 12 months.
AGEN's SMR Rating (100) in the Biotechnology industry is in the same range as EBS (100). This means that AGEN’s stock grew similarly to EBS’s over the last 12 months.
AGEN's Price Growth Rating (34) in the Biotechnology industry is in the same range as EBS (45). This means that AGEN’s stock grew similarly to EBS’s over the last 12 months.
AGEN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EBS (100). This means that AGEN’s stock grew similarly to EBS’s over the last 12 months.
AGEN | EBS | |
---|---|---|
RSI ODDS (%) | 1 day ago86% | N/A |
Stochastic ODDS (%) | 1 day ago90% | 1 day ago83% |
Momentum ODDS (%) | 1 day ago74% | 1 day ago77% |
MACD ODDS (%) | 1 day ago83% | 1 day ago74% |
TrendWeek ODDS (%) | 1 day ago83% | 1 day ago76% |
TrendMonth ODDS (%) | 1 day ago83% | 1 day ago76% |
Advances ODDS (%) | 5 days ago85% | 7 days ago76% |
Declines ODDS (%) | 1 day ago89% | 1 day ago89% |
BollingerBands ODDS (%) | 1 day ago90% | 1 day ago90% |
Aroon ODDS (%) | 1 day ago67% | 1 day ago85% |
A.I.dvisor indicates that over the last year, AGEN has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if AGEN jumps, then TAOX could also see price increases.
Ticker / NAME | Correlation To AGEN | 1D Price Change % | ||
---|---|---|---|---|
AGEN | 100% | -8.93% | ||
TAOX - AGEN | 91% Closely correlated | -6.60% | ||
ALLR - AGEN | 87% Closely correlated | -3.81% | ||
NRXP - AGEN | 83% Closely correlated | -3.12% | ||
PALI - AGEN | 81% Closely correlated | -1.92% | ||
AXON - AGEN | 42% Loosely correlated | -0.59% | ||
More |
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMRX could also see price increases.
Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
---|---|---|---|---|
EBS | 100% | -5.07% | ||
AMRX - EBS | 38% Loosely correlated | -1.78% | ||
HROW - EBS | 38% Loosely correlated | -3.51% | ||
SIGA - EBS | 35% Loosely correlated | -2.33% | ||
VTRS - EBS | 31% Poorly correlated | -2.30% | ||
ANIP - EBS | 30% Poorly correlated | -1.83% | ||
More |